Statistics
DISEASE, SECONDARY
The RAPIDO trial was powered for the primary endpoint (DrTF) but not for any secondary endpoints, including LRF reported here. LRF analyses were performed on an intention-to-treat basis on all eligible patients. LRR analyses were performed in all eligible patients who underwent an R0 or R1 resection (and in 2 nonoperated patients who later developed progressive disease). Proportions were compared with χ